The fate of an antibody labelled with zirconium-89 in cynomolgus macaques

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background Preclinical pharmacokinetic studies of therapeutic antibodies in non-human primates are desired because of the difficulty in extrapolating ADME data from animal models to humans. We evaluated the pharmacokinetics of 89 Zr-labelled anti-KLH human IgG and its metabolites to confirm their non-specific/physiological accumulation in healthy cynomolgus macaques. Methods Selected IgG was conjugated to desferrioxamine (DFO), labelled with 89 Zr, and injected into healthy cynomolgus macaques (9–16 MBq of 89 Zr-IgG/head). PET/CT images at the whole-body level were acquired at different time points, and standard uptake values (SUV) in regions of interest, such as the heart, liver, spleen, kidneys, bone, and muscles, were calculated. The distribution of a shortened antibody variant, 89 Zr-Fab, as well as that of [ 89 Zr]Zr-DFO and [ 89 Zr]Zr-oxalate, the expected metabolites of 89 Zr-IgG, was also assessed. Results After 89 Zr-IgG injection, the SUV in the heart, vertebral body, and muscle decreased, in line with the 89 Zr concentration decrease in the circulation, whereas radioactivity increased over time in the kidneys and liver. Autoradiography of the renal sections indicated that most of the 89 Zr-IgG radioactivity accumulated in the renal cortex. Relatively high accumulation in the kidneys was also observed in 89 Zr-Fab-injected macaques, and renal autoradiographs of these animals showed that the renal cortex was the preferred accumulation site. However, [ 89 Zr]Zr-DFO was rapidly excreted into the urine, whereas [ 89 Zr]Zr-oxalate was highly accumulated in the epiphysis of the long bones and vertebral body. Conclusion In the non-human primate cynomolgus macaque, 89 Zr-IgG accumulated in the kidneys and the liver. However, [ 89 Zr]Zr-DFO and 89 Zr did not accumulate in these organs. This preclinical pharmacokinetic study performed with human IgG in a non-human primate model using PET is of great significance as it sheds light on the basic fate and distribution of 89 Zr-IgG.

Article activity feed